News

A research proposal with total funding of $33.1m involving a collaboration among CureVac, Sanofi Pasteur and In-Cell-Art, a French biotech company contributing its nanoparticle technology, has been selected

The collaboration is believed to make use of the academic and clinical research strengths of both Canada and the UK to drive the research on innovative alternatives to

The project commenced after the biology team at the DDU screened one of their collections of compounds against the malaria parasite, healthcanal.com reported. Over a span of 18

Words+ is known to provide products and services and is commited to the field of augmentative communication. Simulations Plus chairman and CEO Walt Woltosz said Words+ provides computer-based

Scil Proteins took up the process development and early stage GMP manufacturing for a recombinant protein candidate. Scil Proteins CEO Ulrike Fiedler said the company is happy that

Fibrocaps is a dry powder topical fibrin sealant comprising of a mixture of fibrinogen and thrombin blood clotting proteins, which stop bleeding during or after surgery. The study

Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, chronic obstructive pulmonary disease (COPD), gastrointestinal disorders, psoriasis and other dermatological conditions. BioFocus will

Injectafer (US brand name of Ferinject) is a non-dextran intravenous iron replacement therapy comprising Ferric carboxymaltose as the active pharmaceutical ingredient. The first trial compared Injectafer to either

The placebo-controlled, randomized study was designed to assess drug’s safety, tolerability along with pharmacokinetic parameters. In the Phase 1 SAD study, the maximum tolerated single dose was defined